Related Experiment Video

Updated: Jun 21, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Response to sequential treatment schedules in childhood epilepsy: risk for development of refractory epilepsy

J Ramos-Lizana1, P Aguilera-López, J Aguirre-Rodríguez

  • 1Pediatric Neurology Unit, Department of Pediatrics, Torrecárdenas Hospital, Almería, Spain. jramoslizana@telefonica.net

Seizure
|August 7, 2009
PubMed

Insights

Many children with epilepsy achieve seizure control with sequential treatments, and only a small percentage develop refractory epilepsy. This study highlights the effectiveness of ongoing therapeutic adjustments in pediatric epilepsy management.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Therapeutics

Background:

  • Epilepsy is a common neurological disorder in children.
  • Identifying effective treatment strategies is crucial for long-term outcomes.
  • Understanding the risk of refractory epilepsy informs clinical practice.

Purpose of the Study:

  • To evaluate treatment response in children with epilepsy undergoing sequential drug regimens.
  • To determine the incidence and risk factors for developing refractory epilepsy in pediatric patients.
  • To analyze the long-term seizure control rates in childhood epilepsy.

Main Methods:

  • Prospective follow-up of 343 children diagnosed with epilepsy before age 14.
  • Defined seizure control as a 2-year seizure-free period.
  • Defined refractory epilepsy as failure of >2 drugs with persistent seizures for ≥18 months.

Main Results:

  • Seventy percent of patients achieved seizure control by 5 years, and 86% by 10 years.
  • Fifty-nine percent were controlled with the first antiepileptic drug.
  • Among those who failed initial treatments, subsequent regimens led to control in 39% (after first failure), 23% (after second), and 12% (after third).
  • The cumulative risk of developing refractory epilepsy was 8% at 6 years and 12% at 10 years.

Conclusions:

  • A substantial number of children with epilepsy can achieve seizure control through sequential treatment adjustments.
  • The development of refractory epilepsy is relatively uncommon in the pediatric population studied.
  • These findings support the continued use of trial-and-error with multiple antiepileptic drugs in managing childhood epilepsy.
Abstract

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...